Jiuzhou Pharmaceutical(SH:603456) Xin Lang Cai Jing·2025-08-06 01:28Financial Performance - The company's total revenue for the first half of 2025 was 2.871 billion yuan, an increase of 107 million yuan compared to the same period last year, representing a year-on-year growth of 3.86% [1] - The net profit attributable to shareholders was 526 million yuan, an increase of 50.84 million yuan year-on-year, reflecting a growth of 10.70% [1] - The net cash inflow from operating activities was 845 million yuan, which is an increase of 526 million yuan compared to the same period last year, showing a significant year-on-year increase of 164.50% [1] Profitability and Efficiency Ratios - The latest asset-liability ratio is 19.86%, a decrease of 3.99 percentage points compared to the same period last year [3] - The latest gross profit margin is 37.45%, which is an increase of 0.03 percentage points from the previous quarter and an increase of 2.24 percentage points year-on-year [3] - The latest return on equity (ROE) is 6.04%, an increase of 0.38 percentage points compared to the same period last year [3] - The diluted earnings per share (EPS) is 0.59 yuan, an increase of 0.06 yuan year-on-year, reflecting an 11.32% growth [3] - The total asset turnover ratio is 0.26 times, an increase of 0.01 times year-on-year, representing a growth of 3.34% [3] - The inventory turnover ratio is 1.02 times, an increase of 0.07 times compared to the same period last year, indicating a year-on-year increase of 7.67% [3] Shareholder Structure - The number of shareholders is 53,700, with the top ten shareholders holding a total of 448 million shares, accounting for 50.38% of the total share capital [3] - The largest shareholder is Zhejiang Zhongbei Jiuzhou Group Co., Ltd., holding 31.8% of the shares [3]